Tixel for dry eye: the thermomechanical treatment for stubborn meibomian gland dysfunction

Tixel is one of the newer additions to the dry eye toolkit, and it works on the same underlying problem as LipiFlow and IPL: meibomian gland dysfunction (MGD), the blocked-oil-gland problem behind most evaporative dry eye. Because it is newer, the evidence is thinner, and we think you deserve to see exactly how thin.

What Tixel does

Tixel is a thermomechanical device. A tip made of many tiny pyramids is briefly brought into contact with the skin of the eyelids, transferring controlled heat into the tissue. Around the lids, that warmth is intended to reduce inflammation and improve the flow of oil from the meibomian glands. In the published studies it was applied to the upper and lower lids as three treatments two weeks apart. Because it treats the lid skin rather than the eye, it is being explored for people whose dry eye is driven by lid-margin and gland inflammation.

The pilot study: promising, but nobody to compare against

The first clinical report was a pilot trial of 40 patients aged 45 and over (80 eyes) with evaporative dry eye due to MGD (Safir et al., Contact Lens & Anterior Eye, 2022). Everyone had three Tixel treatments two weeks apart and was followed for an average of 2.1 months (give or take 0.6 months). There was no control group: every patient was treated, and each was compared only with their own starting point.

• Symptoms (SPEED II questionnaire, 0 to 28): 16.5 to 11.8.
• Tear break-up time (how long the tear film stays stable): 2.7 to 6.5 seconds.
• Corneal staining (surface damage, 0 to 5): 2.0 to 0.5.
• MGD score: 2.7 to 1.2.
• Lubricant drop use: 3.4 to 1.9 times a day.

All of these changes were statistically significant (P < 0.001), and vision improved very slightly (0.10 to 0.08 logMAR). No major side effects were reported. These are mean differences within one group, meaning the average change from before to after; no 95% confidence intervals were given, and the authors themselves said randomised, double-blind studies are still needed.

The six-month extension: durable, but only in people who responded

A later paper reported what happened six months on (Sadri et al., Journal of Ocular Pharmacology and Therapeutics, 2025). It is a single-arm extension of a randomised, masked, multicentre pivotal study, but it enrolled only responders: people whose tear break-up time had already improved by at least 2.5 seconds at one or three months. Twenty-one people (42 eyes) were followed.

• Tear break-up time: an average gain of 5.2 seconds over baseline (P < 0.001).
• Gland secretion score: +18.2 points (P < 0.0001).
• Symptoms (OSDI, 0 to 100): a 24.3-point reduction (P = 0.0004).
• No ocular adverse events.

Two of the authors are employees of Novoxel, the company that makes Tixel. That does not make the data wrong, but it is a reason to wait for independent confirmation. More importantly, a study that follows only the people who responded cannot tell you how likely you are to respond in the first place; it can only say that among those who did, benefit tended to hold for six months.

What the studies can't tell us

Neither published report includes a sham or untreated comparison in its own analysis, so the numbers above cannot separate the effect of Tixel from the effect of being in a study, using drops more carefully, or the natural ups and downs of dry eye. The pilot was small, followed people for about two months, and had wide variation between patients (the standard deviations are large). The extension excluded non-responders, so the true response rate in an unselected clinic population is not known from these papers. The randomised pivotal study the extension refers to had not been published as a full paper at the time of writing. There is also no head-to-head comparison with LipiFlow or IPL, so nothing here shows that Tixel is better, or worse, than the better-established options. In short: encouraging early data, not yet the kind of evidence that should make anyone choose Tixel over an alternative by default.

How to think about a newer treatment

An emerging treatment with promising but still-growing evidence is best chosen deliberately, not by default. Tixel is one option among several, and whether it is the right one depends on your pattern of dry eye, which is why measurement comes first. A good clinician will tell you honestly where Tixel sits relative to LipiFlow and IPL for your particular eyes, and none of these treatments should be sold as a cure. Dry eye is a chronic condition that is managed rather than switched off.

Being assessed in New Zealand

Tixel is among the treatments offered through the Dry Eye Specialist Group. Assessment starts by measuring your tear film and imaging your glands, so the treatment is matched to what your eyes need rather than to whatever machine is in the room. You can find your nearest clinic or call 0800 349 379. The Dry Eye Evaluation is a paid consultation. The New Zealand Eye Research Centre tracks the developing evidence for these newer options.

This article is general information and not a substitute for a clinical assessment. Whether Tixel suits you depends on an examination of your own eyes.

References

Sourced and verified via PubMed.

• Safir M, Hecht I, Ahimor A, et al. The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease - A pilot prospective clinical trial. Cont Lens Anterior Eye. 2022;45(6):101741. PMID 35864019. https://doi.org/10.1016/j.clae.2022.101741
• Sadri E, Verachtert A, Parkhurst GD, et al. Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study. J Ocul Pharmacol Ther. 2025;41(5):237-243. PMID 40238710. https://doi.org/10.1089/jop.2025.0033